Immunogenicity and reactogenicity of haemophilus influenzae type b - meningococcus group b outer membrane protein conjugate vaccine in children 2-60 months of age

Ziad M Shehab, Parvin Azimi, Basim I. Asmar, Mary Gail Dunphy, Elia M. Ayoub, Adnan S. Dajani

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Haemophilus influenzae b - Neisseria meningitidis group B outer membrane protein conjugate vaccine (Hib-OMP) was given to 571 children 2-60 months of age. Two doses of Hib-OMP were given, 2 months apart, to 2-11 month old infants, and a single dose to children 12-60 month old. Sera were obtained from a subset of vaccinees at each immunization, and at follow-up 1 month and 1 year after immunization. Geometric mean antibody concentration (μg/ml) before and after full immunization were respectively 0.111 and 3.549 for 2-3 month old, 0.108 and 5.048 for 4-5 month old, 0.082 and 6.933 for 6-11 month old; they were 0.103 and 3.500 for 12-17 month old, 0.167 and 7.791 for 18-23 month old and 0.243 and 12.781 for children ≥24 months. Detectable antibody (≥0.125 μg/ml) failed to develop in 2/399 (0.5% after primary immunization, and 12/252 (4.8% lost detectable antibody 1 year later. Six of these 12 infants were <12 month old. The vaccine was immunogenic as early as 3-5 months of age. The need for booster immunization needs to be assessed.

Original languageEnglish (US)
Pages (from-to)763-769
Number of pages7
JournalScandinavian Journal of Infectious Diseases
Volume23
Issue number6
DOIs
StatePublished - 1991

Fingerprint

Haemophilus influenzae type b
Conjugate Vaccines
Neisseria meningitidis
Immunization
Membrane Proteins
Antibodies
Secondary Immunization
Vaccines
Serum

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Immunology

Cite this

Immunogenicity and reactogenicity of haemophilus influenzae type b - meningococcus group b outer membrane protein conjugate vaccine in children 2-60 months of age. / Shehab, Ziad M; Azimi, Parvin; Asmar, Basim I.; Dunphy, Mary Gail; Ayoub, Elia M.; Dajani, Adnan S.

In: Scandinavian Journal of Infectious Diseases, Vol. 23, No. 6, 1991, p. 763-769.

Research output: Contribution to journalArticle

@article{4e2aec0412db46d3ba8fcd539206a2f9,
title = "Immunogenicity and reactogenicity of haemophilus influenzae type b - meningococcus group b outer membrane protein conjugate vaccine in children 2-60 months of age",
abstract = "Haemophilus influenzae b - Neisseria meningitidis group B outer membrane protein conjugate vaccine (Hib-OMP) was given to 571 children 2-60 months of age. Two doses of Hib-OMP were given, 2 months apart, to 2-11 month old infants, and a single dose to children 12-60 month old. Sera were obtained from a subset of vaccinees at each immunization, and at follow-up 1 month and 1 year after immunization. Geometric mean antibody concentration (μg/ml) before and after full immunization were respectively 0.111 and 3.549 for 2-3 month old, 0.108 and 5.048 for 4-5 month old, 0.082 and 6.933 for 6-11 month old; they were 0.103 and 3.500 for 12-17 month old, 0.167 and 7.791 for 18-23 month old and 0.243 and 12.781 for children ≥24 months. Detectable antibody (≥0.125 μg/ml) failed to develop in 2/399 (0.5{\%} after primary immunization, and 12/252 (4.8{\%} lost detectable antibody 1 year later. Six of these 12 infants were <12 month old. The vaccine was immunogenic as early as 3-5 months of age. The need for booster immunization needs to be assessed.",
author = "Shehab, {Ziad M} and Parvin Azimi and Asmar, {Basim I.} and Dunphy, {Mary Gail} and Ayoub, {Elia M.} and Dajani, {Adnan S.}",
year = "1991",
doi = "10.3109/00365549109024305",
language = "English (US)",
volume = "23",
pages = "763--769",
journal = "Infectious Diseases",
issn = "2374-4235",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Immunogenicity and reactogenicity of haemophilus influenzae type b - meningococcus group b outer membrane protein conjugate vaccine in children 2-60 months of age

AU - Shehab, Ziad M

AU - Azimi, Parvin

AU - Asmar, Basim I.

AU - Dunphy, Mary Gail

AU - Ayoub, Elia M.

AU - Dajani, Adnan S.

PY - 1991

Y1 - 1991

N2 - Haemophilus influenzae b - Neisseria meningitidis group B outer membrane protein conjugate vaccine (Hib-OMP) was given to 571 children 2-60 months of age. Two doses of Hib-OMP were given, 2 months apart, to 2-11 month old infants, and a single dose to children 12-60 month old. Sera were obtained from a subset of vaccinees at each immunization, and at follow-up 1 month and 1 year after immunization. Geometric mean antibody concentration (μg/ml) before and after full immunization were respectively 0.111 and 3.549 for 2-3 month old, 0.108 and 5.048 for 4-5 month old, 0.082 and 6.933 for 6-11 month old; they were 0.103 and 3.500 for 12-17 month old, 0.167 and 7.791 for 18-23 month old and 0.243 and 12.781 for children ≥24 months. Detectable antibody (≥0.125 μg/ml) failed to develop in 2/399 (0.5% after primary immunization, and 12/252 (4.8% lost detectable antibody 1 year later. Six of these 12 infants were <12 month old. The vaccine was immunogenic as early as 3-5 months of age. The need for booster immunization needs to be assessed.

AB - Haemophilus influenzae b - Neisseria meningitidis group B outer membrane protein conjugate vaccine (Hib-OMP) was given to 571 children 2-60 months of age. Two doses of Hib-OMP were given, 2 months apart, to 2-11 month old infants, and a single dose to children 12-60 month old. Sera were obtained from a subset of vaccinees at each immunization, and at follow-up 1 month and 1 year after immunization. Geometric mean antibody concentration (μg/ml) before and after full immunization were respectively 0.111 and 3.549 for 2-3 month old, 0.108 and 5.048 for 4-5 month old, 0.082 and 6.933 for 6-11 month old; they were 0.103 and 3.500 for 12-17 month old, 0.167 and 7.791 for 18-23 month old and 0.243 and 12.781 for children ≥24 months. Detectable antibody (≥0.125 μg/ml) failed to develop in 2/399 (0.5% after primary immunization, and 12/252 (4.8% lost detectable antibody 1 year later. Six of these 12 infants were <12 month old. The vaccine was immunogenic as early as 3-5 months of age. The need for booster immunization needs to be assessed.

UR - http://www.scopus.com/inward/record.url?scp=0026316462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026316462&partnerID=8YFLogxK

U2 - 10.3109/00365549109024305

DO - 10.3109/00365549109024305

M3 - Article

C2 - 1815340

AN - SCOPUS:0026316462

VL - 23

SP - 763

EP - 769

JO - Infectious Diseases

JF - Infectious Diseases

SN - 2374-4235

IS - 6

ER -